GlassScriptPhysician profile
Tu Thi Phan
NPI 1689078156
$3,113.50
in general payments reported to CMS, 2019-2025
25 companies · $545 in 2025
The $545 reported for 2025 was more than what 75% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.28 · 2022: $709 · 2023: $1,049 · 2024: $795 · 2025: $545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,324 · Education: $64.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,323.57 |
| Education | $64.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $476.95 | 2022-2025 | |
| Novo Nordisk INC | $361.02 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $327.33 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $314.70 | 2023-2025 | |
| Lilly USA, LLC | $209.15 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $194.68 | 2022-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $183.07 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $166.11 | 2022-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.75 | 2021-2024 | Jardiance |
| Dexcom, INC. | $141.69 | 2023 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Astellas Pharma US INC | $99.10 | 2023-2024 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $64.84 | 2022 | |
| Exact Sciences Corporation | $61.71 | 2023-2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $55.17 | 2024-2025 | Gemtesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $54.28 | 2025 | Caplyta |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $38.59 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.13 | 2024 | |
| Dynavax Technologies Corporation | $34.07 | 2022-2024 | Heplisav-B |
| Teva Pharmaceuticals USA, INC. | $24.89 | 2023 | Austedo Xr |
| Novartis Pharmaceuticals Corporation | $19.68 | 2022 | |
| Lundbeck LLC | $18.37 | 2024 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $18.22 | 2024 | Rexulti |
| Phathom Pharmaceuticals, INC. | $17.52 | 2024 | Voquezna |
| Currax Pharmaceuticals LLC | $17.27 | 2022 | |
| Mylan Specialty L.P. | $12.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tu Phan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.